CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade BridgeBio Pharma, Inc. - BBIO CFD

32.43
0%
Market Trading Hours* (UTC) Open now
Closes on Monday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.21
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

BridgeBio Pharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 32.44
Open* 34.13
1-Year Change* 270.58%
Day's Range* 32.14 - 34.13
52 wk Range 6.64-36.36
Average Volume (10 days) 1.19M
Average Volume (3 months) 32.67M
Market Cap 4.93B
P/E Ratio -100.00K
Shares Outstanding 173.97M
Revenue 9.43M
EPS -3.91
Dividend (Yield %) N/A
Beta 0.99
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 32.44 -1.25 -3.71% 33.69 34.25 32.03
Dec 7, 2023 33.53 1.37 4.26% 32.16 33.64 32.16
Dec 6, 2023 32.34 0.72 2.28% 31.62 32.92 31.25
Dec 5, 2023 31.54 0.13 0.41% 31.41 32.13 30.70
Dec 4, 2023 31.88 1.27 4.15% 30.61 32.31 30.27
Dec 1, 2023 30.89 2.44 8.58% 28.45 30.91 27.78
Nov 30, 2023 28.66 0.14 0.49% 28.52 29.60 28.27
Nov 29, 2023 28.42 -0.39 -1.35% 28.81 29.53 28.32
Nov 28, 2023 28.78 -0.67 -2.28% 29.45 29.91 28.34
Nov 27, 2023 29.72 0.57 1.96% 29.15 30.10 28.66
Nov 24, 2023 29.36 0.22 0.75% 29.14 29.90 28.91
Nov 22, 2023 29.43 0.98 3.44% 28.45 29.43 28.13
Nov 21, 2023 28.24 -0.36 -1.26% 28.60 28.75 28.00
Nov 20, 2023 29.18 0.51 1.78% 28.67 30.00 28.65
Nov 17, 2023 29.20 0.22 0.76% 28.98 29.53 28.36
Nov 16, 2023 28.81 -0.64 -2.17% 29.45 29.46 28.38
Nov 15, 2023 29.45 0.57 1.97% 28.88 30.81 28.45
Nov 14, 2023 29.43 0.40 1.38% 29.03 29.73 28.70
Nov 13, 2023 27.46 0.35 1.29% 27.11 27.77 26.03
Nov 10, 2023 27.05 0.02 0.07% 27.03 27.07 26.33

BridgeBio Pharma, Inc. Events

Time (UTC) Country Event
Wednesday, February 21, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 BridgeBio Pharma Inc Earnings Release
Q4 2023 BridgeBio Pharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 77.648 69.716 8.249 40.56 0
Revenue 77.648 69.716 8.249 40.56 0
Cost of Revenue, Total 3.434 3.114 0 2.5 0
Gross Profit 74.214 66.602 8.249 38.06 0
Total Operating Expense 589.85 646.348 482.731 307.216 164.333
Selling/General/Admin. Expenses, Total 143.189 192.21 145.684 94.353 43.587
Research & Development 399.462 451.024 337.047 207.947 140.073
Unusual Expense (Income) 43.765 2.416 -19.327
Operating Income -512.202 -576.632 -474.482 -266.656 -164.333
Interest Income (Expense), Net Non-Operating 35.05 -45.645 -32.64 -20.719 -0.818
Other, Net -7.5 35.823 1.634 -1.21 -4.3
Net Income Before Taxes -484.652 -586.454 -505.488 -288.585 -169.451
Net Income After Taxes -484.652 -586.454 -505.488 -288.585 -169.451
Minority Interest 3.469 23.915 56.764 27.998 38.702
Net Income Before Extra. Items -481.183 -562.539 -448.724 -260.587 -130.749
Net Income -481.183 -562.539 -448.724 -260.587 -130.749
Income Available to Common Excl. Extra. Items -481.183 -562.539 -448.724 -260.587 -130.749
Income Available to Common Incl. Extra. Items -481.183 -562.539 -448.724 -260.587 -130.749
Diluted Net Income -481.183 -562.539 -448.724 -260.587 -130.749
Diluted Weighted Average Shares 147.473 144.357 117.995 105.099 115
Diluted EPS Excluding Extraordinary Items -3.26285 -3.89687 -3.80289 -2.47944 -1.13695
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.96609 -3.89687 -3.80289 -2.45645 -1.30501
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.641 1.826 1.87 0.338 73.746
Revenue 1.641 1.826 1.87 0.338 73.746
Total Operating Expense 147.74 127.989 131.102 129.454 153.922
Selling/General/Admin. Expenses, Total 36.122 31.108 31.862 31.188 36.426
Research & Development 107.488 92.861 90.902 92.511 108.4
Operating Income -146.099 -126.163 -129.232 -129.116 -80.176
Interest Income (Expense), Net Non-Operating -14.645 -15.004 -15.898 -17.408 88.433
Other, Net 0.041 -1.565 4.56 6.331 -10.816
Net Income Before Taxes -160.703 -142.732 -140.57 -140.193 -2.559
Net Income After Taxes -160.703 -142.732 -140.57 -140.193 -2.559
Minority Interest 2.804 2.576 2.979 2.854 -7.297
Net Income Before Extra. Items -157.899 -140.156 -137.591 -137.339 -9.856
Net Income -157.899 -140.156 -137.591 -137.339 -9.856
Income Available to Common Excl. Extra. Items -157.899 -140.156 -137.591 -137.339 -9.856
Income Available to Common Incl. Extra. Items -157.899 -140.156 -137.591 -137.339 -9.856
Diluted Net Income -157.899 -140.156 -137.591 -137.339 -9.856
Diluted Weighted Average Shares 160.535 152.646 149.365 147.938 146.685
Diluted EPS Excluding Extraordinary Items -0.98358 -0.91818 -0.92117 -0.92836 -0.06719
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.96158 -0.89611 -0.86968 -0.89445 -0.00995
Cost of Revenue, Total 0.599 0.651 0.647 0.739 0.7
Gross Profit 1.042 1.175 1.223 -0.401 73.046
Unusual Expense (Income) 3.531 3.369 7.691 5.016 8.396
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 548.853 888.858 642.824 568.622 445.223
Cash and Short Term Investments 471.922 836.663 607.093 545.993 436.086
Cash & Equivalents 376.689 393.772 356.082 363.773 436.086
Prepaid Expenses 21.922 32.269 35.592 22.629 7.087
Other Current Assets, Total 55.009 19.926 0.139 2.05
Total Assets 623.036 1012.79 703.588 631.679 464.941
Property/Plant/Equipment, Total - Net 25.247 45.973 36.833 5.625 1.575
Property/Plant/Equipment, Total - Gross 1.806
Accumulated Depreciation, Total -0.231
Long Term Investments 31.144 17.05
Other Long Term Assets, Total 20.224 33.027 23.931 26.288 1.093
Total Current Liabilities 121.428 135.069 95.648 60.385 32.577
Accounts Payable 11.558 11.884 8.945 8.852 13.509
Accrued Expenses 101.714 122.89 79.567 47.455 15.062
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 8.156 0 5.55 4.078 4.006
Total Liabilities 1877.65 1883.21 645.682 223.225 150.062
Total Long Term Debt 1707.61 1705.05 477.43 91.791 54.507
Long Term Debt 1707.61 1703.81 475.857 91.791 54.507
Minority Interest 9.693 4.835 49.98 67.522 62.483
Other Liabilities, Total 38.917 38.252 22.624 3.527 0.495
Total Equity -1254.62 -870.414 57.906 408.454 314.879
Preferred Stock - Non Redeemable, Net 478.865
Common Stock 0.157 0.154 0.125 0.124 3.373
Retained Earnings (Accumulated Deficit) -1918.15 -1436.97 -888.755 -440.031 -167.359
Total Liabilities & Shareholders’ Equity 623.036 1012.79 703.588 631.679 464.941
Total Common Shares Outstanding 150.626 147.343 122.849 123.658 115
Short Term Investments 95.233 442.891 251.011 182.22
Redeemable Preferred Stock 0
Additional Paid-In Capital 938.703 841.53 1021.34 848.107
Other Equity, Total -0.328 -0.132 0.192 0.254
Current Port. of LT Debt/Capital Leases 0.295 1.586
Capital Lease Obligations 1.245 1.573
Treasury Stock - Common -275 -275 -75
Intangibles, Net 28.712 44.934
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 587.67 432.884 552.702 548.853 642.219
Cash and Short Term Investments 543.265 383.794 491.293 471.922 591.977
Cash & Equivalents 505.213 302.438 407.368 376.689 483.235
Short Term Investments 38.052 81.356 83.925 95.233 108.742
Total Receivables, Net
Prepaid Expenses 22.583 20.546 25.145 21.922 25.521
Total Assets 655.008 503.661 625.68 623.036 728.74
Property/Plant/Equipment, Total - Net 21.745 22.861 24.098 25.247 27.341
Long Term Investments
Other Long Term Assets, Total 18.676 20.401 20.767 20.224 29.87
Total Current Liabilities 106.065 110.12 96.596 121.428 119.194
Accounts Payable 4.472 3.874 4.076 11.558 10.158
Accrued Expenses 95.001 100.036 85.845 101.714 101.518
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 6.592 6.21 6.675 8.156 7.518
Total Liabilities 1862.55 1865.68 1851.34 1877.65 1867.16
Total Long Term Debt 1721.08 1718.94 1713.29 1707.61 1698.69
Long Term Debt 1721.08 1718.94 1713.29 1707.61 1698.69
Capital Lease Obligations
Minority Interest 13.808 12.385 12.052 9.693 8.044
Other Liabilities, Total 21.597 24.242 29.405 38.917 41.226
Total Equity -1207.54 -1362.02 -1225.67 -1254.62 -1138.42
Common Stock 0.18 0.168 0.167 0.157 0.156
Additional Paid-In Capital 1459.6 1128.1 1106.64 938.703 917.333
Retained Earnings (Accumulated Deficit) -2392.35 -2215.35 -2057.46 -1918.15 -1780.56
Treasury Stock - Common -275 -275 -275 -275 -275
Other Equity, Total 0.034 0.063 -0.012 -0.328 -0.348
Total Liabilities & Shareholders’ Equity 655.008 503.661 625.68 623.036 728.74
Total Common Shares Outstanding 174.132 161.42 160.435 150.626 149.367
Accounts Receivable - Trade, Net
Other Current Assets, Total 21.822 28.544 36.264 55.009 24.721
Redeemable Preferred Stock 0 0 0 0
Intangibles, Net 26.917 27.515 28.113 28.712 29.31
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -484.652 -586.454 -505.488 -288.585 -169.451
Cash From Operating Activities -419.494 -497.934 -399.714 -253.587 -136.643
Cash From Operating Activities 6.771 5.843 0.245
Non-Cash Items 24.047 83.736 90.84 45.913 10.072
Cash Interest Paid 54.443 29.774 15.322 6.092 1.574
Changes in Working Capital 34.34 -1.059 14.934 -10.915 22.491
Cash From Investing Activities 453.147 -200.826 -52.993 -217.253 -21.036
Capital Expenditures -6.321 -13.246 -7.518 -5.138 -18.178
Other Investing Cash Flow Items, Total 459.468 -187.58 -45.475 -212.115 -2.858
Cash From Financing Activities -13.134 736.446 447.189 398.792 501.548
Financing Cash Flow Items -0.724 -163.695 -41.939 -7.272 14.196
Issuance (Retirement) of Stock, Net 8.076 -179.536 -60.872 368.946 430.974
Issuance (Retirement) of Debt, Net -20.486 1079.68 550 37.118 56.378
Net Change in Cash 20.519 37.686 -5.518 -72.048 343.869
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -142.732 -484.652 -344.082 -203.889 -201.33
Cash From Operating Activities -144.322 -419.494 -326.251 -191.088 -160.635
Non-Cash Items 28.579 24.047 -9.872 -20.128 42.625
Cash Interest Paid 22.059 54.443 47.575 25.435 18.809
Changes in Working Capital -31.802 34.34 22.592 29.463 -3.814
Cash From Investing Activities 12.298 453.147 435.182 288.325 138.623
Capital Expenditures -0.012 -6.321 -5.52 -4.761 -0.859
Other Investing Cash Flow Items, Total 12.31 459.468 440.702 293.086 139.482
Cash From Financing Activities 150.249 -13.134 -19.511 -20.956 -0.16
Financing Cash Flow Items 5.231 -0.724 -2.192 -1.596 -1.23
Issuance (Retirement) of Stock, Net 145.018 8.076 3.167 1.126 1.07
Issuance (Retirement) of Debt, Net -20.486 -20.486 -20.486 0
Net Change in Cash 18.225 20.519 89.42 76.281 -22.172
Cash From Operating Activities 1.633 6.771 5.111 3.466 1.884
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Kohlberg Kravis Roberts & Co. L.P. Private Equity 18.0966 31060971 0 2023-06-30 MED
Viking Global Investors LP Investment Advisor/Hedge Fund 14.6359 25120991 -1500000 2023-07-18 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.7973 11666929 -385611 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.6765 8026757 513094 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.1187 7069360 1926347 2023-06-30 LOW
Kumar (Neil) Individual Investor 4.1142 7061605 0 2023-08-17 LOW
Aisling Capital Management LP Investment Advisor/Hedge Fund 3.5354 6068125 0 2023-06-30 LOW
Laurion Capital Management LP Hedge Fund 2.767 4749343 1236584 2023-06-30 HIGH
Cormorant Asset Management, LP Hedge Fund 2.429 4169179 -388235 2023-06-30 LOW
HHLR Advisors, Ltd. Investment Advisor/Hedge Fund 1.744 2993447 -984963 2023-06-30 MED
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.4756 2532716 1090284 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4096 2419370 166212 2023-06-30 LOW
Frazier Healthcare Partners Venture Capital 1.1587 1988876 817226 2023-06-30 LOW
Sequoia Capital Partners Inc. Venture Capital 1.0839 1860364 0 2023-06-30 LOW
Perceptive Advisors LLC Private Equity 1.019 1748933 -158100 2023-06-30 MED
Fidelity Management & Research Company LLC Investment Advisor 0.9677 1660883 -443351 2023-06-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 0.9514 1632986 -599035 2023-06-30 MED
Citi Investment Research (US) Research Firm 0.8317 1427516 -119529 2023-06-30 MED
Homcy (Charles J) Individual Investor 0.7127 1223286 2459 2023-08-16 LOW
Octagon Capital Advisors LP Hedge Fund 0.7103 1219200 -118960 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BridgeBio Pharma, Inc. Company profile

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; Columbia University; Mount Sinai; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California.
Industry: Biopharmaceuticals

3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Gold

1,993.91 Price
-0.660% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

16,069.30 Price
-0.060% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

42,061.65 Price
-3.890% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

71.12 Price
-0.210% 1D Chg, %
Long position overnight fee -0.0213%
Short position overnight fee -0.0006%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading